Phenex Pharmaceuticals AG (Phenex) today announced the achievement of a milestone in the collaboration with Janssen Biotech, Inc. (Janssen), which triggers a 6M US$ payment by Janssen. The milestone payment relates to a R&D collaboration between Phenex and Janssen, with a total potential value of 135 M USD, initiated in late 2012, to jointly discover RORgt inhibitors for the treatment of chronic inflammatory and autoimmune diseases. … Read More

CEVEC Pharmaceuticals GmbH (CEVEC), the expert in the production of tailor-made recombinant glycoproteins and gene therapy vectors, today announced that the Company will collaborate with PlasmidFactory, the leading contract manufacturer and service provider for plasmid and minicircle DNA. … Read More

CEVEC Pharmaceuticals GmbH (CEVEC), the expert in the production of tailor-made recombinant glycoproteins and gene therapy vectors, Provecs Medical GmbH (Provecs), a biopharmaceutical company specialized in the development of cancer microenvironment immunotherapeutics based on adenoviral vector technology , and medac Gesellschaft fuer klinische Spezialpraeparate GmbH (medac), a pharmaceutical company specialized in the diagnosis and treatment of oncological, urological and autoimmune diseases, today announced that the companies have agreed on a broad collaboration for the research, development, manufacture and clinical development of adenoviral vectors for use in oncology indications. … Read More

Berlin, February 21st, 2017 – R3Coms, the R3 – Reliable Realtime Radio Communications GmbH, has been selected by the jury of Startup Autobahn to take part in its Program #2 starting in March 2017. The decision was made after the participation of R3Coms in the Startup Autobahn Selection Day earlier this month. In this new ... Read More

Agreement marks an important step in establishing CAP(R) technologies as the new global industrial standard for viral vector and vaccine development Cologne, Germany, February 09, 2017 – CEVEC Pharmaceuticals GmbH (CEVEC), the expert in the production of tailor-made recombinant glycoproteins and gene therapy vectors, today announced that it has signed an exclusive license agreement with ... Read More

(Martinsried, 12.01.2017) With the beginning of a new fiscal year SIRION Biotech GmbH, located at the Innovation and Start-Up Center for Biotechnology in Martinsried/Planegg near Munich, reports an annual growth of 140% to 4 million Euros in revenue, and profitability – just in time to celebrate its 10th year in the business. Decisive for this ... Read More

Ludwigshafen, Germany, January 06, 2017 – Phenex Pharmaceuticals AG (Phenex) yesterday announced that the company has received a 100 M USD milestone payment from Gilead Sciences, Inc. of Foster City, CA, U.S.A., for its program with GS-9674 targeting nonalcoholic steatohepatitis (NASH). GS-9674 is a novel, synthetic and nonsteroidal FXR agonist which was originally developed by ... Read More

CEVEC Pharmaceuticals GmbH (CEVEC), the expert in the production of tailor-made recombinant glycoproteins and gene therapy vectors, today announced that is has submitted a Biologics Master File (BB-MF) for its human cell substrate CAP® to the U.S. Food and Drug Administration’s (FDA) Center for Biologics Evaluation and Research (CBER). … Read More

Johannes-Philipp Berendes and Moritz Burmeister have been named new Managing Directors at Iconicfuture. With a lean and entrepreneurial business approach the two young managers aim to make the company more flexible and agile to operate successfully in the rapidly changing games market. … Read More

AYOXXA Biosystems GmbH, an international biotechnology company, and Märzhäuser Wetzlar GmbH & Co KG, a leading precision equipment manufacturer, joined forces to develop a dedicated benchtop device for the analysis of LUNARIS™ Multiplex assays. The AYOXXA Reader AR01 expands the technology platform to offer researchers a complete, flexible and user-friendly system for multiprotein analysis. The device was approved for routine laboratory work use in biomedical research. … Read More

A Zurich-based martech company, has opened its London office in Paddington and expanded its team to include Matthew Beck, Greg Carroll and Rahul Bathia. … Read More

CEVEC Pharmaceuticals GmbH (CEVEC), the expert in the production of tailor-made recombinant glycoproteins and gene therapy vectors, today announced a strengthening of the Company reflective of its strategic progress. … Read More

A strategic collaboration between caprotec bioanalytics and Charles River has been established to offer their proprietary protein capture technology for phenotypic screening target deconvolution. … Read More

The Fintech company Knip reinforces its management team: Emily Kruse joined Knip AG as CFO in April 2016. … Read More

KNIP, a mobile digital Insurance manager, has been selected as one of the FinTech50 2016 companies. More than 1200 companies across Europe aimed for this award. The jury consists of the biggest names in FinTech. … Read More

The Swiss FinTech Award has been initiated by the Finanz und Wirtschaft Forum located in Zurich. Thursday night, the first Swiss FinTech Award has been granted to the two most promising and convincing Swiss Fintech-solutions Knip and Sentifi. … Read More

Inc. magazine ranked Viewster No. 10 on the 2016 Inc. 5000 list of fastest growing private companies in Europe and testifies Viewster a growth of 1,551% over the past three years. Average Growth Rate of Inc. 5000 Europe Companies is 226+% with Annual Revenue of €110 Billion. … Read More

AUSTIN, Texas–(BUSINESS WIRE)–Shopgate Inc., the leading SaaS retail app platform, adds Apple TV apps to their portfolio of shopping channels that already include iPhone, iPad and Android apps. Now, retailers can not only build apps designed for mobile devices, but also create retail apps designed for the recently launched Apple TV app store. With only ... Read More

The appointment of Sonja Glauert (37) as Head of Customer Relationship Management (CRM), previously Bosch eBike Service Manager, at the beginning of February brings an experienced eBike expert on board to enhance the COBI team. Christian Lortz (37) previously worked as Product Manager at SMART technologies and joined COBI as Senior Product Manager at the beginning of January. The engineering team has also been strengthened with the arrival of Ken Kölzer (29), former engineer at De’Longhi Braun Household, who joined COBI in February as Mechanical & Quality Engineer. … Read More

Phenex Pharmaceuticals AG (Phenex) today announced that the company will receive a milestone payment from Gilead Sciences, Inc. of Foster City, CA, U.S.A. for the initiation of a Phase 1 study for GS-9674, a novel, synthetic and non-steroidal FXR agonist, in non-alcoholic Steatohepatitis (NASH). In January 2015, Gilead acquired the Farnesoid X Receptor (FXR) program from Phenex, in a deal valued at 470 million US$. The FXR program is comprised of new small molecule therapeutics for the treatment of liver diseases, including NASH. … Read More

Hendrik Maat, CEO of zadego GmbH and its corporate branch easybooking, announces the opening of a long-planned new fourth office in Sopron, Hungary. This step has been taken earlier than planned due to a strong increase in customers in 2015 and is part of the very successful ongoing European rollout of the program. … Read More

Gilles Raymond, News Republic’s founder and CEO, likes to use big numbers to describe his business: its app is available in 40 countries and 29 languages; news sourcing comes from 1500 separate deals with information providers, ranging from Reuters to The Guardian or Business Insider in the Western world, but also Hearst China, Sohu News (China), Baidu ... Read More

EndoPredict Spares Breast Cancer Patients Unnecessary Chemotherapy Cologne, November 12th, 2015 – The EndoPredict gene expression test developed and manufactured in Cologne now becomes available to breast cancer patients in the world’s most populous country: in China. This is made possible by a collaboration between the manufacturer, Sividon Diagnostics, and the Shanghai-based company Virchow Laboratories ... Read More

AYOXXA is Member of the International EYE-RISK Consortium LUNARIS™ multiplexing platform is applied in epidemiological studies for AMD   Cologne, October 22nd, 2014 AYOXXA Biosystems GmbH, an international biotechnology company, is one of two industrial partners of EYE-RISK, a large biomedical consortium bringing together the expertise of ten renown scientific and clinical institutions and a ... Read More

CEVEC and BioLamina combine technology leadership for commercial production of recombinant laminins for ex vivo cell therapies   CEVEC adds laminins as CAP®Go application in the field of ex vivo cell culture products for cell therapies CEVEC’s CAP®Go to displace HEK293 and CHO cell lines in GMP manufacturing BioLamina to further grow its leading high ... Read More

Frank Ubags (CEO CEVEC Pharmaceuticals) is giving “insights from industry”. To see the full interview please click here: www.news-medical.net … Read More

Creathor Venture co-leads biggest Swiss Fintech financing round in Knip alongside Route 66 Ventures and QED with a total of USD 15.7 Million   Digital insurance manager Knip disrupts the b2c insurance broker market   Zurich, 26 October 2015 – With the Knip app, users can easily view and manage their portfolio of insurance policies ... Read More

Berlin based IT company Kyto, founded in 2013, secured a seven digit investment. Besides the participation of new investor Müller Medien and significant financial support via the Pro FIT program of Investitionsbank Berlin (IBB), existing investors Projects A Ventures, Creathor Ventures and Bauer Venture Partners contributed to the new investment. Kyto is an international software ... Read More

Agreement enables fully scalable, industrial lentivirus vector production Collaboration represents an important step in the roll-out of CEVEC’s strategy to position CAP®GT technology as the industrial standard for the production of lentiviral vectors for commercial gene therapy applications   Cologne, Germany, September 17, 2015 CEVEC Pharmaceuticals GmbH (CEVEC), the expert in the production of tailor-made ... Read More

Cologne, September 14th, 2014 AYOXXA Biosystems GmbH, an international biotechnology company, announced that Dr. Gerald Möller has joined the company’s supervisory board as an independent board director and chairman of the board. With 40 years of experience in Pharma, Diagnostics and Biotech, Dr. Möller will guide AYOXXA’s strategic expansion from life science research into disease ... Read More

LUNARIS™ is AYOXXA’s unique  technology platform combining the robustness and quality of classical immunoassays with the performance of modern bead-based methods delivered on a solid surface. LUNARIS™ BioChips enable researchers to perform simultaneous detection of multiple analytes in pg/mL concentrations, requiring minimal sample volumes.   AYOXXA offers a flexible and scalable system for 32 to ... Read More

Munich/Bad Homburg, June 10, 2015 Creathor Venture, one of the leading European Venture Capital firms, announces the exit of Danato GmbH, the popular German e-commerce market place for gifts, to Gruner + Jahr. Danato (www.danato.com) was founded in 2011 by Jörg Überla and has been growing rapidly since. Supported by Creathor and the other investors ... Read More

News Republic won “Best Mobile Media and Publishing App” at Mobile World Congress 2015 in Barcelona. The award was presented by John Cleese on behalf of MWC’s 300 judges. Judges Comments: “Genuinely a step forward in terms of curation, intuitive design and connecting editorial interests for consumers. A pleasure to use.”   For more information ... Read More

As part of the EU RESPONSIFY research project, immune markers in tumours, which not only affect the prognosis of a breast cancer patient but also predict the response to certain treatments, were identified for the first time. In patients with HER2-positive or triple negative breast cancer (TNBC) in particular, the results of the research point the way ahead. These types of breast carcinomas are characterised by an aggressive progression of the disease, meaning that the development of new treatment strategies is particularly necessary for these Patient Groups. ...Read More

Testdroid Professional Services – A Dedicated Specialist for Automating Your App Testing Dear Testdroiders, As you might know, we’ve offered professional services for creating test scripts and integrating all Testdroid products into your continuous integration environments, build systems, various different tools and other scripts. Today, we’re launching a new service that will bring you even ... Read More

Deconstructing Continuous Quality Process for Mobile App Development Dear Testdroiders, Mobile app users and gamers are more demanding than ever before. According to McKinsey and their analysts, the application related revenues have reached $25 billion already in 2013 and are on the way to reach more than $70 billion by 2017. In this study, the ... Read More

Insiteo, the leader in indoor location and proximity marketing deployed its services in Toulouse-Blagnac Airport to empower the new mobile application released this month. The application, available for iPhone and Android devices, has been specifically designed for frequent flyers with an innovative “find-my-car” feature. Indeed, the parking lot is automatically stored in the application thanks ... Read More

Validation of new protein multiplexing technology platform in the ophthalmic domain Cologne and Singapore 03. February 2015 AYOXXA, an international biotech company with headquarters in Cologne, has signed an agreement with the Singapore Eye Research Institute (SERI), one of the leading international eye research institutes. AYOXXA and SERI will work together on validating the company’s ... Read More

Creathor’s portfolio company Phenex Pharmaceuticals announces acquisition of its development program for non-alcoholoic steatohepatitis (NASH) and other liver diseases by Gilead Sciences, Inc., for up to $470m January 7, 2015 – Bad Homburg, Ludwigshafen/Heidelberg, Foster City, CA Gilead Sciences, Inc. (Nasdaq: GILD) and Phenex Pharmaceuticals AG, a Creathor portfolio company, today announced the signing of ... Read More

  Frankfurt / Eschborn, December 1, 2014 Accovion, a leading independent European full-service Contract Research Organization, headquartered in Frankfurt (Eschborn), Germany, announced today the establishement of a new subsidiary in Lyon, France, as it continues its expansion across Europe. Together with offices in Italy, Poland, Russia, Romania, Spain, Czech Republic and United Kingdom, Accovion is ... Read More